Genetic analysis of autoimmune encephalitis related to NMDAR antibodies
GEnome-wide Association Study in N-methyl-D-Aspartate Receptor and Other autoiMmune Encephalitis.
This study is trying to find out how genetics play a role in autoimmune encephalitis linked to NMDAR antibodies to improve diagnosis and treatment for those affected.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon) |
| Trial ID | NCT05225883 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on autoimmune encephalitis, particularly cases associated with antibodies against the N-methyl-D-aspartate receptor (NMDAR). It aims to characterize the genetic factors involved by conducting a genome-wide association study (GWAS) on patients with well-defined antibody profiles and clinical presentations. The study will collect and analyze clinical and biological data to better understand the underlying mechanisms of this condition. By identifying genetic markers, the research seeks to enhance diagnosis and treatment strategies for affected individuals.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with confirmed NMDAR antibodies and a clinical presentation consistent with autoimmune encephalitis.
Not a fit: Patients without well-characterized antibodies or those with alternative diagnoses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic tools and targeted therapies for patients with autoimmune encephalitis.
How similar studies have performed: Previous studies have shown promise in understanding autoimmune encephalitis through genetic analysis, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presence of well-characterized antibodies in serum or cerebrospinal fluid; * Clinical picture compatible with the detected antibody based on the literature Exclusion Criteria: * Absence of complete clinicobiological data. * Alternative diagnosis
Where this trial is running
Lyon
- Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes — Lyon, France (Recruiting)
Study contacts
- Study coordinator: Jerome HONNORAT, MD
- Email: jerome.honnorat@chu-lyon.fr
- Phone: (33) 4 72 35 78 08
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.